Related Experiment Video
Updated: Aug 19, 2026
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
Published on: June 17, 2016
Dexamethasone inhibition of rat hepatoma growth and alpha-fetoprotein synthesis
Abstract:
The effect of dexamethasone on hepatoma growth and differentiation, as well as the production of alpha-fetoprotein (AFP) and albumin, was investigated. Treatment of rats with dexamethasone strongly reduced (by 83 to 98%) the serum levels of AFP in rats bearing Morris hepatomas 7777, 8994, 7288c , and 9618A2 . Reduced AFP levels were due in part to a large reduction in tumor load in dexamethasone-treated rats. Hepatoma weights, on the average, were reduced by 64 to 90% relative to controls, while a large bowel transplantable tumor was affected only slightly. Lower serum AFP levels in rats with hepatomas 7777, 8994, and 9618A2 also resulted from reduced AFP synthesis, as indicated by lower cytoplasmic AFP levels. Cytoplasmic albumin levels were higher in dexamethasone-treated rats bearing hepatomas 7777, 8994, and 7288c than they were in rats which did not receive dexamethasone. RNA dot hybridization also indicated that dexamethasone reduced the amount of AFP mRNA in hepatoma 7777 while increasing albumin mRNA. Two-dimensional gel electrophoresis of tumor cytosol proteins showed that dexamethasone reduced synthesis of all AFP variants which could be detected by this technique. A number of abundant hepatoma-associated and liver-associated proteins were not significantly affected by dexamethasone.
Insights
Dexamethasone significantly reduced hepatoma growth and alpha-fetoprotein (AFP) production in rats. This steroid treatment also decreased AFP messenger RNA levels and increased albumin messenger RNA in tumors.
Area of Science:
- Hepatocellular carcinoma research
- Endocrinology
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) is a major global health concern.
- Alpha-fetoprotein (AFP) is a key biomarker for HCC, but its regulation is complex.
- Dexamethasone, a synthetic glucocorticoid, has known effects on cellular differentiation and gene expression.
Purpose of the Study:
- To investigate the impact of dexamethasone on hepatoma growth and differentiation.
- To determine the effect of dexamethasone on the production of alpha-fetoprotein (AFP) and albumin.
- To elucidate the molecular mechanisms underlying dexamethasone's effects on AFP and albumin synthesis in hepatoma models.
Main Methods:
- Treatment of rats bearing various Morris hepatoma lines with dexamethasone.
- Quantification of serum AFP and albumin levels.
- Analysis of cytoplasmic AFP and albumin levels.
- RNA dot hybridization to assess AFP and albumin mRNA levels.
- Two-dimensional gel electrophoresis of tumor cytosol proteins.
Main Results:
- Dexamethasone treatment markedly reduced serum AFP levels (83-98%) and hepatoma weights (64-90%) in multiple hepatoma models.
- Reduced AFP levels were associated with decreased tumor load and reduced AFP synthesis, indicated by lower cytoplasmic AFP and AFP mRNA.
- Dexamethasone increased cytoplasmic albumin levels and albumin mRNA in specific hepatoma lines.
- Dexamethasone reduced the synthesis of all detectable AFP variants and did not significantly affect other abundant hepatoma-associated proteins.
Conclusions:
- Dexamethasone effectively suppresses hepatoma growth and AFP production in vivo.
- The drug modulates AFP and albumin gene expression, impacting key proteins involved in hepatoma biology.
- These findings highlight the potential of dexamethasone or related glucocorticoids in managing HCC, particularly concerning AFP regulation.
